These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia. Khountham S; Shindiapina P; Mo X; Lachowiez C; Wiczer T; Mousa L; Rogers KA; Andritsos LA; Woyach JA; Byrd JC; Spurgeon SE; Awan FT Leuk Lymphoma; 2021 Mar; 62(3):716-721. PubMed ID: 33210562 [No Abstract] [Full Text] [Related]
12. Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment. Gounari M; Ntoufa S; Gerousi M; Vilia MG; Moysiadis T; Kotta K; Papakonstantinou N; Scarfò L; Agathangelidis A; Fonte E; Ranghetti P; Nenou A; Xochelli A; Coscia M; Tedeschi A; Stavroyianni N; Muzio M; Stamatopoulos K; Ghia P Leukemia; 2019 Apr; 33(4):1030-1051. PubMed ID: 30607020 [No Abstract] [Full Text] [Related]
13. Four-Factor Score for Outcome of Ibrutinib Treatment in Chronic Lymphocytic Leukemia: Prognostic Model for Risk Group Definition. Stilgenbauer S J Clin Oncol; 2021 Feb; 39(6):551-553. PubMed ID: 33048620 [No Abstract] [Full Text] [Related]
14. Ibrutinib does not reverse disease- and treatment-related hypogammaglobulinaemia associated with chronic lymphocytic leukemia. Khan S; Durairaj S; Phumphukhieo P; Holding S; Allsup D Leuk Lymphoma; 2021 Jul; 62(7):1786-1789. PubMed ID: 33596758 [No Abstract] [Full Text] [Related]
15. [Richter syndrome successfully treated with ibrutinib monotherapy: two case reports]. Fujinami H; Kusumoto S; Masaki A; Ohshima Y; Tachita T; Sasaki H; Marumo Y; Yoshida T; Narita T; Ito A; Ri M; Komatsu H; Inagaki H; Iida S Rinsho Ketsueki; 2019; 60(10):1462-1467. PubMed ID: 31695008 [TBL] [Abstract][Full Text] [Related]
16. Central nervous system immune reconstitution inflammatory syndrome after ibrutinib therapy for Richter transformation. Chan KL; Lokan J; Tam CS; Lew TE; Prince HM Leuk Lymphoma; 2017 Jan; 58(1):207-210. PubMed ID: 27326828 [No Abstract] [Full Text] [Related]
17. Ibrutinib in the real world patient: many lights and some shades. Ghia P; Cuneo A Haematologica; 2016 Dec; 101(12):1448-1450. PubMed ID: 27903711 [No Abstract] [Full Text] [Related]
18. Front-line chemo-immunotherapy is not inferior to ibrutinib in CLL. van Gelder M; Tournilhac O; Te Raa D; Visser HPJ Ann Oncol; 2021 Nov; 32(11):1442-1443. PubMed ID: 34428511 [No Abstract] [Full Text] [Related]
19. Modulated expression of adhesion, migration and activation molecules may predict the degree of response in chronic lymphocytic leukemia patients treated with ibrutinib plus rituximab. Peragine N; De Propris MS; Intoppa S; Milani ML; Mariglia P; Mauro FR; Raponi S; Soddu S; Cuneo A; Rigolin GM; Del Giudice I; Foà R; Guarini A Haematologica; 2020 Oct; 106(5):1500-1503. PubMed ID: 33054124 [No Abstract] [Full Text] [Related]
20. Central nervous system involvement in chronic lymphocytic leukemia: a case report and review of literature. Qin LY; Geng Y; Mu JF; Wang WJ; Zhang CX; Gao YN; He JX J Med Case Rep; 2024 Jul; 18(1):315. PubMed ID: 38982482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]